预约演示

ProJenX ALS treatment gets back on the map after partial FDA hold

2024-03-29

临床1期

Prosetin was discovered by researchers at Columbia University, who went on to form ProJenX to examine the drug in ALS.

Prosetinis back on the map after the FDA lColumbia Universitynical hold on a phase ProJenXcal trial for an amyotroALSc lateral sclerosis (ALS) drug.

ProJenX4 kinase (MAP4K) inhibitor proFDAin was set to be tested in an early-stage trial called PRO-101 withamyotrophic lateral sclerosis (ALS)o have ALS. While the volunteer portion has completed, the regulator stepped in to halt Part 1c of the trial.

Now,MAP4 kinase MAP4Koving on dosprosetinents with ALS. The company did not say when the hold PRO-101n applied or provide an explanation of the FDA’ALSoncerns. Requests for comment on those details went unreturned as of publication.

"FollProJenXecent clinical trial application authoriALSions in Canada and Europe, we are very pleased that FDA has lifted this partial clinical hFDA, which previously limited prosetin dose levels in study PRO-101 in the U.S.," ProJenX Chief Operating Officer Erin Fleming said in a Thursday release. "The FDA's decision allows us to fully pursue a global strategy to bring this promising investigational treatment to people with ALS and other neurodegenerative diseases."

Don't miss: #FierceMadness: The Best Biotech Name TournamentFDA prosetin PRO-101 ProJenX FDA ALS neurodegenerative diseases

Canadian and European regulators okayed the trial in November 2023 and February, respectively.

Prosetin was discovered by researchers at Columbia University, who went on to form ProJenX to examine the drug in ALS. MAP4K inhibition is believed to provide motor neuron protection across multiple patient stem cell-derived models of ALS. So, prosetin was developed to be a potent inhibitor of the pathway with efficacy in motor neuron rescue and preferential distribution to the central nervous system.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构